NCT03759379: A reported trial by Alnylam Pharmaceuticals
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03759379 |
|---|---|
| Title | HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 14, 2019 |
| Completion date | Nov. 10, 2020 |
| Required reporting date | Nov. 10, 2023, midnight |
| Actual reporting date | July 12, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |